Literature DB >> 225317

The fat cell adenylate cyclase system. Characterization and manipulation of its bimodal regulation by GTP.

D M Cooper, W Schlegel, M C Lin, M Rodbell.   

Abstract

GTP evoked both an activatory and an inhibitory response from adipocyte adenylate cyclase. This paper describes the persistence of the bimodal response under a variety of assay conditions. Additionally, manipulations are described which eliminate one or other of these actions. Treatment of adipocyte plasma membranes with cholera toxin A1 peptide and NAD+ abolishes the inhibitory phase of GTP action while preserving the activating phase. Treatment of the membranes with p-hydroxymercuriphenylsulfonic acid eliminates the activatory phase while maintaining the inhibitory processes mediated by GTP in adipocytes normally coexist and operate through different pathways since either phase can be abolished leaving the other intact. Adenosine and its purine-modified analogs inhibit fat cell adenylate cyclase in the GTP inhibitory phase (Londos, C., Cooper, D. M. F., Schlegel, W., and Rodbell, M. (1978) Proc. Natl. Acad. Sci. U.S.A. 75, 5362-5366). When this effect of GTP is abolished by either cholera toxin or Gpp(NH)p pretreatment, the inhibitory action of adenosine analogs is also lost. These data suggest a central role for GTP in mediating both activation and inhibition of adenylate cyclase by agents which act through cell surface receptors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225317

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Changes in adenosine receptors during differentiation of 3T3-F442A cells to adipocytes.

Authors:  K Ravid; J M Lowenstein
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

2.  Isoproterenol stimulates shift of G proteins from plasma membrane to pinocytotic vesicles in rat adipocytes: a possible means of signal dissemination.

Authors:  K Haraguchi; M Rodbell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Effect of 1,25-dihydroxyvitamin D3 on cyclic AMP responses to hormones in clonal osteogenic sarcoma cells.

Authors:  M Kubota; K W Ng; T J Martin
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

4.  The novel thermogenic beta-adrenergic agonist Ro 16-8714 increases the interscapular brown-fat beta-receptor-adenylate cyclase and the uncoupling-protein mRNA level in obese (fa/fa) Zucker rats.

Authors:  P Muzzin; J P Revelli; D Ricquier; M K Meier; F Assimacopoulos-Jeannet; J P Giacobino
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

5.  Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors.

Authors:  A R Hughes; M W Martin; T K Harden
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

Review 6.  Activation and attenuation of adenylate cyclase. The role of GTP-binding proteins as macromolecular messengers in receptor--cyclase coupling.

Authors:  L E Limbird
Journal:  Biochem J       Date:  1981-04-01       Impact factor: 3.857

Review 7.  Adenylate cyclase and membrane fluidity. The repressor hypothesis.

Authors:  R Salesse; J Garnier
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

8.  Inhibition of dopamine-activated adenylate cyclase and dopamine binding by opiate receptors in rat striatum.

Authors:  S Gentleman; M Parenti; N H Neff; C B Pert
Journal:  Cell Mol Neurobiol       Date:  1983-03       Impact factor: 5.046

9.  Epidermal growth factor stimulates rat cardiac adenylate cyclase through a GTP-binding regulatory protein.

Authors:  B G Nair; H M Rashed; T B Patel
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

10.  Acceleration of the adipocyte adenylate cyclase turn-off reaction by inhibitory hormonal factors.

Authors:  K H Jakobs; K Aktories; G Shultz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.